Navigation Links
ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion)

tere induced an anaphylactoid type reaction consistent with hypersensitivity reactions, including acute increases in blood histamine levels and decreased blood pressure. In contrast, no hypersensitivity reactions, including no elevations in histamine levels and no changes in blood pressure were observed following dosing with ANX-514.

ADVENTRX is continuing to conduct additional preclinical pharmacokinetic testing of ANX-514 to compare this product candidate with the approved version of the product, marketed under the brand name Taxotere. The Company currently plans to seek guidance from the FDA with respect to the appropriateness of a Section 505(b)(2) NDA regulatory path for ANX-514, and pending agreement on clinical protocol design with the FDA, initiate a marketing-enabling clinical trial of ANX-514 in 2007.

About ANX-514 (docetaxel emulsion)

ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, a product marketed under the brand name Taxotere. ANX-514 is designed to eliminate the need for multi-day immunosuppressant premedication. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of allergic reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers. In connection with a Section 505(b)(2) NDA covering ANX-514, ADVENTRX must certify that all applicable Taxotere patents have expired prior to the manufacture, use or sale of ANX-514.

About Section 505(b)(2)

Section 505(b)(2) of the U.S. Food, Drug & Cosmetic Act (FDCA) allows the Food and Drug Administration (FDA) to approve a follow-on drug on the basis of data in
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:4/17/2015)... ASSESS shows   plasma circulating ... viable alternative to tumour biopsy   IGNITE ... advanced NSCLC   AstraZeneca today presented results from ... DNA (ctDNA) testing for epidermal growth factor receptor (EGFR) mutation ... cancer (NSCLC) in clinical practice. [ 1 ] ...
(Date:4/17/2015)... April 17, 2015  Over the next five years, the ... grow, with ArcView predicting that 14 more states will legalize ... The U.S. market for legal cannabis grew 74 percent in ... Analysts project the market could grow more than fourfold to ... soften their stance on marijuana. Cannabiz Mobile Inc. ...
(Date:4/17/2015)... Apr. 16, 2015 Research and Markets ... of the "The Corporate Reputation of Pharma ... Edition " report to their offering. ... Perspective, is now in its fourth edition. This ... early 2015). For each annual Corporate Reputation report, ...
Breaking Medicine Technology:"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2
... WIRE)--May 30, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB: ... a Phase I,trial of INNO-406, an orally ... or,treatment-intolerant chronic myelogenous leukemia, will be,presented at ... Annual,Meeting. The meeting takes place June 1- ...
... from various,clinical studies including a pivotal Phase III trial ... Nexavar (sorafenib) tablets will be presented at the Annual,Meeting ... USA from June 1 - 5, 2007. , On ... be held on June 4, 2007. Starting at around ...
Cached Medicine Technology:Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
(Date:4/17/2015)... (PRWEB) April 17, 2015 Calvary Hospital recently ... Inc. as Executive Vice President on May 11. The Fund ... and historic mission. Barr succeeds Vincent J. Spinelli, who retired ... agreed to take on and supervise the important work that ... and CEO. “As Calvary continues to expand and bring our ...
(Date:4/17/2015)... Oxytocin is a natural hormone ... to help mothers bond to their newborn, as well ... new studies performed, at NYU Langone Medical Center in ... Medical News Today on April 16, 2015, reveals that ... behavior. The study reveals that, when oxytocin was injected ...
(Date:4/17/2015)... 17, 2015 Mario Badescu ... and perfect facial skin with its unique combination ... blend of energizing botanicals. This cushiony gel-based formula ... cause breakouts and inhibit penetration of special treatments, ... Ivory Palm Seeds, This uncommon exfoliating ingredient is ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 According to ... an estimated 50 million Americans suffer from all types ... skin and eye allergies. Thanks to comprehensive allergy testing ... ( caremedurgentcare.com ), there’s now a way to get ... weather. , “Allergy triggers, or allergens, can vary by ...
(Date:4/17/2015)... April 17, 2015 Cheapquotesautoinsurance.com has released a ... that has a salvage title . , An auto ... under a salvage title if the owner has paid for ... salvage title car is not possible, while in other states, ... released blog post provides more information on the subject. ...
Breaking Medicine News(10 mins):Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 2Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 3Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 3Health News:Mario Badescu Skin Care Launches Botanical Exfoliating Scrub 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 3Health News:Compare Auto Insurance Quotes for Cars With A Salvage Title! 2
... autism have normal-size heads at birth but develop accelerated ... a period that precedes the onset of many behaviors ... to new research from the University of Washingtons Autism ... is present in children who have the early onset ...
... Bay Park to be the focus of this inaugural ... ... An unclimbed mountain near Mount Abbe,in the northern reaches of Alaska,s ... Expedition for Cancer Research, a quest,sponsored by Fred Hutchinson Cancer Research ...
... released environmental estrogen 55 times faster , , WEDNESDAY, Jan. ... water can release a potentially harmful chemical 55 times ... (BPA) is found in the plastics that make up ... packaging. It acts as an environmental estrogen and can ...
... LiquidAgents Healthcare, LLC,has achieved the Gold Seal of ... Commission., LiquidAgents Healthcare, LLC underwent an unannounced, ... how staffing firms,determine the qualifications and competency of ... they monitor staff,s performance., "Health care organizations ...
... survived a heart attack or have been diagnosed with ... death in the United States. In addition to medications, ... are known to reduce the risk for subsequent cardiac ... attack survivors do not follow their doctors advice to ...
... LANSING, Jan. 30 A report issued today ... policy consultancy,based in Washington, D.C., confirms that Blue ... million to the people of Michigan in 2007 ... to improve access to,health coverage at affordable prices. ...
Cached Medicine News:Health News:Accelerated head growth can predict autism before behavioral symptoms start 2Health News:Hutchinson Center Announces First Unclimbed Mountain to be Tackled by Big Expedition for Cancer Research 2Health News:Heating Plastic Bottles Releases Potentially Harmful Chemical 2Health News:Heating Plastic Bottles Releases Potentially Harmful Chemical 3Health News:LiquidAgents Healthcare, LLC Awarded Accreditation from the Joint Commission 2Health News:UMass Medical School study finds patients diagnosed with coronary heart disease continue poor diets 2Health News:UMass Medical School study finds patients diagnosed with coronary heart disease continue poor diets 3Health News:Examination by National Expert Shows Blue Cross Blue Shield of Michigan's Social Mission Contributions Totaled at Least $391 Million in 2007 2Health News:Examination by National Expert Shows Blue Cross Blue Shield of Michigan's Social Mission Contributions Totaled at Least $391 Million in 2007 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: